


PHARMACEUTICAL 2021



AGIOS PHARMACEUTICALS INC. Rank 206 of 409





PHARMACEUTICAL 2021



AGIOS PHARMACEUTICALS INC. Rank 206 of 409

The relative strengths and weaknesses of AGIOS PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AGIOS PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 55% points. The greatest weakness of AGIOS PHARMACEUTICALS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is -136%, being 218% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	636,677
Cost of Goods Sold	2,805
Intangible Assets	0
Liabilities, Current	94,394
Liabilities, Non-Current	97,458
Other Assets	183,984
Other Compr. Net Income	-97
Other Expenses	17,832
Other Liabilities	261,600
Other Net Income	6,611
Property and Equipment	32,291
Research and Development	367,470
Revenues	203,196
Selling, General and Administrative Expense	149,070

Output Variable	Value in 1000 USD
Assets	852,952
Liabilities	453,452
Expenses	537,177
Stockholders Equity	399,500
Net Income	-327,370
Comprehensive Net Income	-327,418
Economic Capital Ratio	-136%